Pull up any clinical AI product deck circulating in 2026 and you will find the same table: benchmark scores, leaderboard rankings, and a column of percentages that climb toward 100. OpenAI’s o1-preview achieved 96% accuracy on MedQA-USMLE and 99% on MMLU Medical Genetics. Google’s Med-Gemini has been reported to achieve strong scores on MedQA. JSL Medical-LLM 78B has been reported to achieve high scores on Medical Genetics benchmarks. The numbers are real. The inference drawn from them, that these systems are clinically ready, is not.
Nature Medicine published a perspective this month arguing exactly that: prospective evidence for conversational medical AI is hard, but non-negotiable. The argument is straightforward on its surface. Benchmarks test recall under controlled conditions. Clinical workflows punish systems under chaotic ones. Ergo, developers must generate prospective, real-world evidence before deployment. The framing sounds reasonable. The consensus around it is growing. And that consensus is the problem, because agreeing that prospective evidence matters is easy, while actually designing trials that can generate it is where the whole enterprise breaks down.
The Leaderboard Illusion
Consider what a 96% accuracy score on MedQA actually measures. The exam draws from a corpus of structured, curated clinical vignettes. The test-taker, human or algorithm, receives a clean question with a defined set of answer choices and no interruptions. Now place that same system in a teaching hospital at 2 a.m., fielding an ambiguous query from a fatigued intern who has misspelled three terms, omitted the patient’s renal function, and is simultaneously managing two other conversations. The benchmark was never measuring performance in that environment. It was measuring performance in an environment that does not exist.
IBM Watson for Oncology learned this at significant cost. Operational between 2017 and 2019, the system generated treatment recommendations built on hypothetical cases created by Memorial Sloan Kettering physicians rather than real patient outcomes, a fact that emerged only after hospitals in India, Thailand, and elsewhere had deployed it. The algorithm performed impressively on the scenarios it was trained to handle. Real oncology presented different scenarios entirely.
The Watson collapse was not a data science failure. It was a human factors and integration failure dressed as one. That distinction matters enormously for how sponsors design validation trials for conversational AI today.
A Consensus Without a Protocol
The venture capital community is moving at a pace that assumes the validation problem is already solved. In 2025, AI companies captured 55% of all health tech funding, up from 37% in 2024 and 29% in 2022. The average health tech deal size climbed 42% year-over-year, from $20.7 million to $29.3 million. With that capital velocity comes an investor timeline that treats benchmark performance as sufficient proof of concept and prospective clinical validation as a post-commercial formality.
Clinicians occupy a different position. The same systems investors are funding land in their workflows as tools they must supervise, correct, and ultimately answer for. A hospitalist who acts on a conversational AI recommendation that misses a drug interaction does not share liability with the algorithm’s developer. That asymmetry shapes how physicians read a product deck: with considerably more skepticism than the funding round suggests is warranted.
Regulators sit in a third position entirely. The FDA released its AI/ML Software as a Medical Device Action Plan in January 2021, acknowledging openly that its traditional regulatory paradigm was not designed for adaptive AI technologies. Five years later, that acknowledgment has not resolved into a clear prospective evidence standard for conversational AI specifically. Sponsors submitting De Novo requests or 510(k)s for conversational clinical AI are navigating guidance that was not written with these systems in mind, in a framework that still treats most AI outputs as passive decision support rather than active clinical intervention.
Three stakeholders, three incompatible timelines, and one shared rhetorical commitment to “rigorous evidence.” Which raises the practical question no product deck answers: what does a prospective validation trial for conversational medical AI actually look like?
Designing for Failure, Not Performance
The Nature Medicine perspective pushes toward RCT-grade evidence. That framing is correct but incomplete. A randomized controlled trial designed to measure conversational AI performance against a primary accuracy endpoint will reproduce the benchmark problem at larger scale. If the outcome measure is “did the system give the right answer,” you have built a very expensive MedQA administration. The outcome measure must be clinical: patient safety events, diagnostic delay, medication errors caught or created, clinician time to decision, and, critically, system behavior at the edges of its training distribution.
Edge behavior is where every clinical AI deployment eventually lives. A conversational system performs well on the modal presentation of a common condition. Its value proposition, and its risk profile, are determined by what it does with the atypical presentation, the co-morbid patient, the query phrased in clinical shorthand, and the scenario that falls outside its training corpus. Trial designs that do not deliberately stress-test those conditions are not generating prospective evidence of clinical safety. They are generating prospective evidence of typical-case performance, which the benchmark already provided at a fraction of the cost.
Human factors endpoints belong in the primary endpoint structure, not the appendix. If a conversational AI system causes a clinician to override their own correct instinct because the interface presented the AI recommendation with inappropriate confidence, a failure mode with well-documented precedent in clinical decision support literature, that event must be captured and reported. A trial that measures only system accuracy while leaving clinician behavior unmeasured has answered the wrong question.
The FDA’s existing human factors guidance for medical devices provides a starting framework, but conversational AI presents challenges that static device guidance does not contemplate. A diagnostic algorithm produces an output. A conversational AI system conducts a dialogue, and the clinical risk emerges from the interaction pattern over time, not from any single output. Designing trials that capture longitudinal interaction patterns, not just endpoint accuracy snapshots, requires methodological development that the field has not yet produced at scale.
Sponsors who move toward that methodological standard now will not just satisfy a future regulatory requirement. They will hold the only asset that actually distinguishes a clinical-grade conversational AI from a very sophisticated chatbot with a medical vocabulary: evidence that the system performs safely when real patients, real clinicians, and real institutional chaos enter the equation. The benchmark proves the algorithm learned the textbook. The prospective trial proves it survived contact with the hospital. Those are not the same thing, and the gap between them is exactly where patients get hurt.
The first sponsor to file a pre-market submission for a conversational medical AI backed by a methodologically rigorous prospective trial, one with human factors endpoints, edge-case stress testing, and longitudinal interaction data, will set the evidentiary bar for every system that follows. Every later filing gets measured against it. The developers currently polishing their MedQA scores should be asking whether they want to set that bar or clear it.
References
- Nature Medicine, “Prospective evidence for conversational medical AI is hard, but non-negotiable”
- arXiv, “Medical AI Benchmark Performance: o1-preview, Med-Gemini, JSL Medical-LLM 78B accuracy on MedQA-USMLE and MMLU”
- Starfish Medical, “FDA Action Plan for AI/ML in Software as a Medical Device (January 2021)”
- Bessemer Venture Partners, “State of Health AI 2026: Funding trends and AI company share of health tech investment”
- Pertama Partners, “15 AI Project Failures and How to Avoid Them: IBM Watson for Oncology case study”
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
